Shield Therapeutics PLC PDMR Acquisition of Shares (7505S)

TIDMSTX

RNS Number : 7505S

Shield Therapeutics PLC

05 October 2017

Shield Therapeutics plc

("Shield" or the "Company")

PDMR Acquisition of Shares

London, UK, 5 October 2017. Shield Therapeutics plc (LSE:STX), a specialty pharmaceutical company focused on secondary care, announces that Carl Sterritt, Chief Executive Officer of the Company, has on 4 October 2017 exercised a call option to acquire 8,814 Ordinary Shares in the Company from Irorph GmbH for consideration of GBP1 per Ordinary Share. Details of the call option are set out in the Company's Admission Document. Following the transaction, Mr Sterritt holds 10,075,261 shares, representing 8.67 % of the Company's issued share capital.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

 
 1    Details of the person discharging managerial 
       responsibilities/person closely associated 
---  ------------------------------------------------------------------- 
 a)   Name                       Carl Sterritt 
---  -------------------------  ---------------------------------------- 
 2    Reason for the notification 
---  ------------------------------------------------------------------- 
 a)   Position/status            CEO and Director of Shield Therapeutics 
                                  plc 
---  -------------------------  ---------------------------------------- 
 b)   Initial                    Initial Notification 
       notification/ 
       Amendment 
---  -------------------------  ---------------------------------------- 
 3    Details of the issuer, emission allowance market 
       participant, auction platform, auctioneer or 
       auction monitor 
---  ------------------------------------------------------------------- 
 a)   Name                       Shield Therapeutics plc 
---  -------------------------  ---------------------------------------- 
 b)   LEI                        213800G74QWY15FC3W71 
---  -------------------------  ---------------------------------------- 
 4    Details of the transaction(s): section to be 
       repeated for (i) each type of instrument; (ii) 
       each type of transaction; (iii) each date; 
       and (iv) each place where transactions have 
       been conducted 
---  ------------------------------------------------------------------- 
 a)   Description                Ordinary shares of 1.5p each in the 
       of the                     capital of the Company 
       financial                  ISIN of Ordinary Shares: GB00BYV81293 
       instrument, 
       type 
       of instrument 
       Identification 
       code 
---  -------------------------  ---------------------------------------- 
 b)   Nature                     Acquisition of Ordinary Shares in 
       of the                     accordance with the terms of a call 
       transaction                option. 
---  -------------------------  ---------------------------------------- 
 c)   Price(s)                   GBP1 per Ordinary Share 
       and volume(s)              Volumes: 8,814 
---  -------------------------  ---------------------------------------- 
 d)   Aggregated 
       information                 8,814 
                                   GBP8,814 
        *    Aggregated volume 
 
 
 
        *    Price 
---  -------------------------  ---------------------------------------- 
 e)   Date                       4 October 2017 
       of the 
       transaction 
---  -------------------------  ---------------------------------------- 
 f)   Place                      Outside a trading venue 
       of the 
       transaction 
---  -------------------------  ----------------------------------------

- Ends -

For further information please contact:

Shield Therapeutics plc +44 (0)207 186 8500

Carl Sterritt, Chief Executive Officer

Karl Keegan, Chief Financial Officer

Nominated Advisor and Joint Broker +44 (0)203 100 2222

Liberum Capital Limited

Christopher Britton/Steve Pearce

Joint Broker +44 (0)207 418 8900

Peel Hunt LLP

James Steel/Dr Christopher Golden

Financial PR Advisor

+44 (0)203 709 5700

Consilium Strategic Communications

Mary-Jane Elliott/Matthew Neal

US Investor Relations

Lazar Partners +1 (212) 867 1762

Fern Lazar/ David Carey

About Shield Therapeutics plc

Shield Therapeutics is a specialty pharmaceutical company focused on the commercialisation and development of late-stage, hospital-focused pharmaceuticals which address areas of unmet medical need. Our clear purpose is to help our patients become people again, by enabling them to enjoy the things that make the difference in their everyday lives. The Group has a marketed product, Feraccru(R), for the treatment of iron deficiency anaemia (IDA) in adult patients with inflammatory bowel disease (IBD) which has exclusive IP rights until the mid-2030's. Shield Therapeutics, headquartered in London, is listed on LSE's AIM under the ticker STX. For more information please visit www.shieldtherapeutics.com.

About Feraccru(R)

Feraccru is Shield's lead product and is a novel therapy for the treatment of IDA. Feraccru received marketing authorisation across Europe in February 2016 for the treatment of IDA in adult patients with IBD and is in the early stages of commercialisation in European markets. The Group is currently completing a pivotal Phase 3 clinical trial of Feraccru in IDA patients with pre-dialysis CKD and expects to announce results of this study around the turn of the year. A positive result is expected to facilitate the filing of an NDA for Feraccru in the US as well as significantly broader commercialisation in Europe and beyond.

This information is provided by RNS

The company news service from the London Stock Exchange

END

DSHLZLLBDBFFFBL

(END) Dow Jones Newswires

October 05, 2017 02:00 ET (06:00 GMT)

Shield Therapeutics (LSE:STX)
Historical Stock Chart
From Jun 2024 to Jul 2024